Provided by Tiger Trade Technology Pte. Ltd.

Spruce Biosciences, Inc.

72.40
+1.552.19%
Post-market: 72.400.00000.00%18:14 EST
Volume:30.00K
Turnover:2.17M
Market Cap:77.16M
PE:-0.88
High:74.40
Open:71.17
Low:71.00
Close:70.85
52wk High:240.00
52wk Low:4.28
Shares:1.07M
Float Shares:877.30K
Volume Ratio:1.28
T/O Rate:3.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-82.4787
EPS(LYR):-96.3944
ROE:-167.93%
ROA:-76.92%
PB:14.33
PE(LYR):-0.75

Loading ...

Spruce Biosciences Reports Long-Term Efficacy of Tralesinidase Alfa in Sanfilippo Syndrome Type B

Reuters
·
Yesterday

Spruce Biosciences Appoints Daven Mody and Bruno Gagnon to Executive Leadership Team

Reuters
·
Feb 03

Spruce Biosciences Reports Positive Long-Term Results for Tralesinidase Alfa in Sanfilippo Syndrome Type B

Reuters
·
Jan 28

Top Premarket Gainers

MT Newswires Live
·
Jan 26

Big-Pharma Partner Harbour BioMed Boosts Stake In Spruce Biosciences

Benzinga
·
Jan 21

Harbour BioMet acquires common stock in Spruce Biosciences

TIPRANKS
·
Jan 20

HBM Holdings Deepens Ties With Spruce Biosciences via Warrant Exercise

TIPRANKS
·
Jan 19

HBM Holdings Acquires 3.8% Stake in Spruce Biosciences

Reuters
·
Jan 19

BRIEF-Spruce Biosciences Secures Up To $50 Million In Growth Capital From Avenue Capital

Reuters
·
Jan 08

Spruce Biosciences Secures $50 Million Loan Facility from Avenue Capital

Reuters
·
Jan 08

Spruce Biosciences Inc - Initial Funding of $15 Mln Extends Cash Runway Into 2027

THOMSON REUTERS
·
Jan 08

Spruce Biosciences Secures up to $50 Million in Growth Capital From Avenue Capital

THOMSON REUTERS
·
Jan 08

BUZZ-Oppenheimer starts Spruce Biosciences with "outperform" rating on rare disease strength

Reuters
·
Dec 23, 2025

Spruce Biosciences Coverage Assumed by HC Wainwright & Co. at Buy

Dow Jones
·
Dec 22, 2025

Refile-Spruce Biosciences, Inc. : H.c. Wainwright Assumes Coverage With Buy Rating and Target Price $220 (Clarifies to Say Assumes Coverage)

THOMSON REUTERS
·
Dec 22, 2025

Spruce Biosciences, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $220

THOMSON REUTERS
·
Dec 22, 2025

Spruce Biosciences Sets New Director Compensation Terms with Stock Options and Retainers

Reuters
·
Dec 15, 2025

Spruce Biosciences Appoints Keli Walbert to Board of Directors

Reuters
·
Dec 15, 2025

Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors

THOMSON REUTERS
·
Dec 15, 2025

Spruce Biosciences Reprices Stock Options to Boost Employee Retention

Reuters
·
Dec 13, 2025